🕒 Created

Abbott reaches $670 million settlement to resolve Gill case and 2,000 additional preterm infant formula lawsuits

Abbott has reached agreements with three law firms to settle the Gill case and claims involving approximately 2,000 other individuals regarding the company's specialty formulas for preterm infants. The settlement, totaling approximately $670 million, resolves the landmark $495 million verdict in the Gill case, where an infant suffered permanent brain damage from necrotizing enterocolitis (NEC). While the settlement is a milestone, it does not conclude the broader litigation. Abbott continues to face roughly 1,700 pending lawsuits involving 12,700 infants. The company maintains that the formulas are safe and necessary, noting that there is no reliable scientific evidence that they cause NEC. Medical authorities, including the FDA and the American Academy of Pediatrics, agree that preterm infant formula is an essential life-saving component of neonatal care. Abbott believes the agreements are in its best long-term interest and represent a constructive step toward resolving the overall litigation.

Sources